DelveInsight’s ‘Burns-Market Insights, Epidemiology, and Market Forecast–2032’ report deliver an in-depth understanding of the Burns historical and forecasted epidemiology as well as the Burns market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The Burns market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Burns market size from 2022 to 2032. The Report also covers current Burns treatment practice, market drivers, market barriers, SWOT analysis, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Some of the Key Facts of the Burns Market Report:
- According to our assessments for the United States, the estimated cases of hospitalized burn patients in 2021 were 76,383.
- Among the EU5 countries, the UK had the highest incident population of burn patients that require medical treatment with 275,829 cases, followed by France (203,690 cases) and Spain (143,209 cases) in 2021. On the other hand, Italy had the lowest incident population (122,890).
- Japan had 328,255 incident cases of burn injuries requiring medical treatment in 2021, the second-highest of all other countries in 7MM after the US.
Key Benefits of the Burns Market report
- The report covers a descriptive overview of Burns, explaining its causes, symptoms, pathophysiology, genetic basis, and currently available therapies.
- Comprehensive insight has been provided into the Burns epidemiology and treatment.
- Additionally, an all-inclusive account of both the current and emerging therapies for Burns is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
- A detailed review of the Burns market; historical and forecasted is included in the report, covering the 7MM drug outreach.
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Burns market.
Got queries? Click here to know more about the Burns Market Landscape
Burn injuries are underappreciated injuries that are associated with substantial morbidity and mortality. Burn injuries, particularly severe burns, are accompanied by an immune and inflammatory response, metabolic changes, and distributive shock that can be challenging to manage and can lead to multiple organ failures. Of great importance is that the injury affects not only physical health but also the patient’s mental health and quality of life. Burn injuries are underappreciated trauma that can affect anyone, anytime and anywhere. The injuries can be caused by friction, cold, heat, radiation, chemical, or electric sources, but most burn injuries are caused by heat from hot liquids, solids, or fire. Although all burn injuries involve tissue destruction due to energy transfer, different causes can be associated with different physiological and pathophysiological responses.
Accurate assessment of the severity of a burn injury is paramount because it forms the basis for all subsequent treatment decisions, triage plans, and assessment of medical futility. Whenever possible, decisions about proceeding after diagnosis and screening should incorporate patient preferences and expectations about the quality of life. Optimal assessment of the severity of burn injury must involve a systematic, methodical approach, such as that described in course materials for the Advanced Trauma Life Support (ATLS) by the American College of Surgeons Committee on Trauma, Emergency Management of the Severe Burn (EMSB) by the Australian and New Zealand Burn Association, and Advanced Burn Life Support (ABLS) by the ABA
Burns Epidemiological Insight
- In 2021, the total incident population of burn injuries that required medical treatment in seven major markets was reported to be 1,864,208.
- The number of hospitalized burn cases in the seven major market is expected to increase at an effective CAGR during the study period, i.e. 2019–2032.
- The estimates suggest the United States had the highest incident population of burn injuries that required medical treatment with 661,900 cases in 2021.
- According to our analysis, after fire/flame (41%), scald was the foremost contributing cause of burn injuries in the US, occupying 31.4% of total incident cases of treatment-taking burn injuries.
Burns Epidemiological Segmentation
- Burns total incident cases
- Burns gender-specific incident cases
- Burns etiology specific incident cases
- Burns Severity Specific Incident Cases
- Burns total incident cases of hospitalized patients
Burns Market Outlook
In the current market scenario, the standard treatment for skin burn involves medications, wound dressings, therapy, and surgery. The treatment goals are to control pain, remove dead tissue, prevent infection, reduce scarring risk, and regain function. The treatment depends on the severity of the burn.
Apart from the pharmacological treatment options, the most important management practice involves surgery. Early autografting then build on these improvements by rapidly closing excised wounds, further reducing infection risk, decreasing pain, and enabling earlier mobilization. If there are concerns about the viability or bacterial load on the wound bed and/or the patient’s stability, allografting is preferred to cover the debrided wound temporarily.
The common principle of skin substitutes is to deliver proteins, growth factors and/or cells via a delivery vehicle or matrix that will then be integrated into the wound and form new autologous skin. Common skin substitutes include cadaver skin (allograft) and porcine skin (xenograft), which provide temporary coverage for up to 14 days before inevitable rejection. To overcome the need for uninjured donor skin in autologous STSG, artificial skin substitutes have been introduced to the market and include TransCyte, CEA, cultured skin substitutes, and various others. Some commercially available skin substitutes are Epicel, StrataGraft, RECELL System, Split thickness skin graft, Kerecis Omega3 products, and several others. The dynamics of the skin burn market are anticipated to change in the coming years due to the improvement in the treatment, incremental healthcare spending across the world, and the expected launch of emerging therapies during the forecast period. Companies like CUTISS AG, RenovaCare, Mallinckrodt Pharmaceuticals, and others across the globe are working toward developing more advanced treatment therapies for skin burns.
Learn more by requesting for sample @ Burns Market Landscape
Burns Key Companies
- CUTISS AG
- Aegle Therapeutics
- And many others
- CellMist System
- EHSG-KF (denovoSkin)
- And many others
- Ongoing research to develop a treatment for severely burned patients
- The abundance of approved therapies
- Rising incidence
- Advancements in burn care treatments and products
- Complications associated with available therapies
- Lack of cost-effective treatment
- Lack of robust clinical pipeline
- Limited awareness on burn care
Table of Contents
- Key Insights
- Report Introduction
- Executive Summary of Burns
- Disease Background and Overview
- Epidemiology and patient population
- The United States
- EU 5
- Burns Emerging Therapies
- Burns Market Outlook
- Market Drivers
- Market Barriers
- Market Access and Reimbursement of Therapies
- Burns Report Methodology
- DelveInsight Capabilities
- About DelveInsight
Click here to read more about Burns Market Landscape
Company Name: DelveInsight Business Research
Contact Person: Adya Kaul
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States